NIAID Study Shows Low-Dose Marburg Vaccine Effective in Macaques | CPT PPP Coverage
Cryptopolytech (CPT) Public Press Pass (PPP)
News of the Day COVERAGE
200000048 – World Newser
•| #World |•| #Online |•| #Media |•| #Outlet |
View more Headlines & Breaking News here, as covered by cryptopolytech.com
NIAID Study Shows Low-Dose Marburg Vaccine Effective in Macaques appeared on globalbiodefense.com by Global Biodefense.
Scientists are working on a promising experimental vaccine against Marburg virus, for which there is no licensed preventive vaccine.
Since its discovery in 1967, Marburg virus has caused over a dozen documented sporadic outbreaks in Africa, with the most recent in Equatorial Guinea and the United Republic of Tanzania.
The VSV-MARV vaccine is based on the same concept as ERVEBO, an FDA-approved vaccine against Ebola virus.
In a new study published in Emerging Microbes and Infections, scientists from NIAID’s Laboratory of Virology determined in cynomolgus macaques that a low dose given two weeks before virus exposure provided robust protection; vaccination one week prior to virus exposure provided limited protection.
Previously the group had determined that high doses of the vaccine were effective. With portions of Africa experiencing multiple Marburg virus outbreaks in 2023, the scientists encourage clinical evaluation of the low-dose VSV-MARV vaccine in preparation for upcoming outbreaks.
Transcriptional profiling of immune responses in NHPs after low-dose, VSV-based vaccination against Marburg virus. Emerging Microbes & Infections, 24 Aug 2023.
FEATURED ‘News of the Day’, as reported by public domain newswires.
View ALL Headlines & Breaking News here.
Source Information (if available)
This article originally appeared on globalbiodefense.com by Global Biodefense – sharing via newswires in the public domain, repeatedly. News articles have become eerily similar to manufacturer descriptions.
We will happily entertain any content removal requests, simply reach out to us. In the interim, please perform due diligence and place any content you deem “privileged” behind a subscription and/or paywall.
CPT (CryptoPolyTech) PPP (Public Press Pass) Coverage features stories and headlines you may not otherwise see due to the manipulation of mass media.
First to share? If share image does not populate, please close the share box & re-open or reload page to load the image, Thanks!